JP2008501339A - Ａａｖベクターの凝集を防ぐための組成物およびその方法 - Google Patents

Ａａｖベクターの凝集を防ぐための組成物およびその方法 Download PDF

Info

Publication number
JP2008501339A
JP2008501339A JP2007515525A JP2007515525A JP2008501339A JP 2008501339 A JP2008501339 A JP 2008501339A JP 2007515525 A JP2007515525 A JP 2007515525A JP 2007515525 A JP2007515525 A JP 2007515525A JP 2008501339 A JP2008501339 A JP 2008501339A
Authority
JP
Japan
Prior art keywords
aggregation
vector
virion
ionic strength
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515525A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン・フレイザー・ライト
ク・グアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35462907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008501339(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of JP2008501339A publication Critical patent/JP2008501339A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Lubricants (AREA)
JP2007515525A 2004-06-01 2005-06-01 Ａａｖベクターの凝集を防ぐための組成物およびその方法 Pending JP2008501339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57599704P 2004-06-01 2004-06-01
US63922204P 2004-12-22 2004-12-22
PCT/US2005/019235 WO2005118792A1 (en) 2004-06-01 2005-06-01 Compositions and methods to prevent aav vector aggregation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012040561A Division JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Publications (1)

Publication Number Publication Date
JP2008501339A true JP2008501339A (ja) 2008-01-24

Family

ID=35462907

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2007515525A Pending JP2008501339A (ja) 2004-06-01 2005-06-01 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2012040561A Expired - Lifetime JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2014014070A Pending JP2014111625A (ja) 2004-06-01 2014-01-29 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2016058761A Pending JP2016195587A (ja) 2004-06-01 2016-03-23 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2018218970A Pending JP2019058177A (ja) 2004-06-01 2018-11-22 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2012040561A Expired - Lifetime JP5769650B2 (ja) 2004-06-01 2012-02-27 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2014014070A Pending JP2014111625A (ja) 2004-06-01 2014-01-29 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2016058761A Pending JP2016195587A (ja) 2004-06-01 2016-03-23 Ａａｖベクターの凝集を防ぐための組成物およびその方法
JP2018218970A Pending JP2019058177A (ja) 2004-06-01 2018-11-22 Ａａｖベクターの凝集を防ぐための組成物およびその方法

Country Status (10)

Country Link
US (4) US7704721B2 (enExample)
EP (3) EP1751275B1 (enExample)
JP (5) JP2008501339A (enExample)
BR (1) BRPI0511764B8 (enExample)
CA (1) CA2569244C (enExample)
DK (2) DK1751275T3 (enExample)
ES (2) ES2647477T3 (enExample)
HU (2) HUE060433T2 (enExample)
MX (3) MXPA06014030A (enExample)
WO (1) WO2005118792A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524101A (ja) * 2016-07-21 2019-09-05 スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2021533757A (ja) * 2018-08-10 2021-12-09 リジェネクスバイオ インコーポレイテッド 組換えａａｖ生成のためのスケーラブルな方法
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP2023536883A (ja) * 2020-08-07 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド 高度に精製されたウイルス粒子のための製剤

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058035A1 (en) * 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20090111099A1 (en) * 2007-10-27 2009-04-30 Yongsheng Ma Promoter Detection and Analysis
US8067241B2 (en) * 2009-08-26 2011-11-29 General Electric Company Method and apparatus for antigen retrieval process
WO2011094198A1 (en) 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
WO2012018628A1 (en) 2010-07-26 2012-02-09 Board Of Regents, The University Of Texas System Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
CA2829774C (en) * 2011-03-14 2019-09-24 National Research Council Of Canada Method of viral production in cells
HK1202434A1 (en) 2011-11-22 2015-10-02 The Children's Hospital Of Philadelphia Virus vectors for highly efficient transgene delivery
WO2013090409A1 (en) * 2011-12-12 2013-06-20 The Children's Hospital Of Philadelphia Large commercial scale lentiviral vector production system and vectors produced thereby
US9974850B2 (en) 2013-01-25 2018-05-22 Board Of Regents, The University Of Texas System Immunogenic compositions and uses thereof
PT3010537T (pt) * 2013-06-17 2019-12-03 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Métodos para a prevenção da agregação de componentes virais
JP6567974B2 (ja) 2013-11-29 2019-08-28 タカラバイオ株式会社 アデノ随伴ウイルスの定量方法
DK3546585T3 (da) 2014-04-25 2025-11-03 Genethon Nukleinsyrer med en modificeret intron til brug i behandlingen af hyperbilirubinæmi
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
US10526583B2 (en) 2014-07-02 2020-01-07 University Of Florida Research Foundation, Incorporated Compositions and methods for purifying recombinant adeno-associated virus
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
EP3230441A4 (en) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
SG11201704919SA (en) 2015-01-13 2017-07-28 Alfa Wassermann Inc Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav)
EP3054007A1 (en) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
WO2017075335A1 (en) 2015-10-28 2017-05-04 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
US11617783B2 (en) 2015-11-16 2023-04-04 Research Institute At Nationwide Children's Hospital Repairing a mutant human titin gene using CRISPR technology
WO2017100676A1 (en) * 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
ES2938833T3 (es) * 2016-03-28 2023-04-17 Ultragenyx Pharmaceutical Inc Métodos de inactivación térmica de adenovirus
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
IL299325B2 (en) 2016-09-12 2025-08-01 Inst Nat Sante Rech Med Acid-alpha glucosidase variants and uses thereof
EP3293259A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293260A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
EP3293203A1 (en) 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
JP7051132B2 (ja) 2016-09-16 2022-04-11 ロイコケア・アクチェンゲゼルシャフト ワクチン接種または遺伝子治療のための効率的なウイルスベクターベースの組成物を得るための新規方法
IL266264B2 (en) * 2016-11-04 2023-11-01 Baxalta Inc Adeno-associated virus formulations
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
US10294452B2 (en) * 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
EP3576796A1 (en) 2017-02-01 2019-12-11 Centre National De La Recherche Scientifique Particles and compositions comprising the same for transfection
US11541131B2 (en) 2017-03-10 2023-01-03 Genethon Treatment of glycogen storage disease III
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
IL274430B2 (en) * 2017-11-08 2025-01-01 Novartis Gene Therapies Inc Means and method for preparing viral vectors and their uses
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
CN111902539B (zh) 2018-02-07 2025-05-16 吉尼松公司 杂合调控元件
WO2019173434A1 (en) 2018-03-06 2019-09-12 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
WO2019210137A1 (en) 2018-04-27 2019-10-31 Voyager Therapeutics, Inc. Methods for measuring the potency of aadc viral vectors
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
WO2019222444A2 (en) 2018-05-16 2019-11-21 Voyager Therapeutics, Inc. Directed evolution
EP3793686A1 (en) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019236949A1 (en) 2018-06-08 2019-12-12 Avexis Inc. Cell-based assay for measuring drug product potency
JP2021529001A (ja) * 2018-06-29 2021-10-28 ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーＷｕｈａｎ Ｎｅｕｒｏｐｈｔｈ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ レーベル遺伝性視神経症を治療するための組成物及び方法
US12391928B2 (en) 2018-06-29 2025-08-19 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
US20210254103A1 (en) 2018-07-02 2021-08-19 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
WO2020014479A1 (en) * 2018-07-11 2020-01-16 Baxalta Incorporated Aav compositions
MX2021000810A (es) 2018-07-24 2021-04-28 Voyager Therapeutics Inc Sistemas y metodos para producir formulaciones de terapia genetica.
FI3833746T3 (fi) 2018-08-08 2023-06-01 Genethon Mini-GDE glykogenoosi III:n hoitamiseksi
AU2019323434A1 (en) 2018-08-20 2021-02-25 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
EP3911410A1 (en) 2019-01-18 2021-11-24 Voyager Therapeutics, Inc. Methods and systems for producing aav particles
CN113766935A (zh) 2019-02-26 2021-12-07 全国儿童医院研究所 β-肌聚糖的腺相关病毒载体递送和肌营养不良症的治疗
WO2020208032A1 (en) 2019-04-08 2020-10-15 Genethon Hybrid promoters for muscle expression
AU2020257570A1 (en) 2019-04-19 2021-10-28 Genethon Gene therapy of fibroblast growth factor 23 related hypophosphatemic diseases
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
CN120137971A (zh) 2019-07-25 2025-06-13 诺华股份有限公司 可调节的表达系统
WO2021030125A1 (en) 2019-08-09 2021-02-18 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
EP4013436A1 (en) 2019-08-14 2022-06-22 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
US11155835B2 (en) 2019-08-19 2021-10-26 The Catholic University Of America Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
SI4017871T1 (sl) 2019-08-21 2024-06-28 Research Institute At Nationwide Children's Hospital Dostava alfa-sarkoglikana z adeno povezanim virusnim vektorjem in zdravljenje mišične distrofije
EP4022070A1 (en) 2019-08-26 2022-07-06 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240108669A1 (en) 2019-10-07 2024-04-04 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
WO2021078834A1 (en) 2019-10-22 2021-04-29 Genethon Chimeric acid-alpha glucosidase polypeptides and uses thereof
EP4048786A1 (en) 2019-10-22 2022-08-31 Genethon Chimeric polypeptides and uses thereof
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
EP4114958A1 (en) 2020-02-21 2023-01-11 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP3913060A1 (en) 2020-05-22 2021-11-24 Genethon Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapy
EP4157301A4 (en) * 2020-06-02 2025-03-19 Janssen Biotech, Inc. Materials and methods for viral purification
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
JP2023539219A (ja) 2020-08-24 2023-09-13 ジェネトン 糖原病ｉｉｉの治療のためのｃ末端切断ｇｄｅ
US20230407328A1 (en) 2020-11-02 2023-12-21 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
CN116917471A (zh) 2020-12-09 2023-10-20 吉尼松公司 溶酶体酸性脂肪酶变体及其用途
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4301768A2 (en) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Controlled expression of viral proteins
US20240307553A1 (en) * 2021-04-01 2024-09-19 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
WO2022236008A1 (en) * 2021-05-07 2022-11-10 Board Of Regents, The University Of Texas System Methods and compositions for transport, storage, and delivery of adeno-associated viral vector and other molecules
JP2024529540A (ja) 2021-08-04 2024-08-06 ジェネトン 筋肉及びｃｎｓにおける遺伝子発現のためのハイブリッドプロモーター
WO2023042104A1 (en) 2021-09-16 2023-03-23 Novartis Ag Novel transcription factors
EP4219726A1 (en) 2021-10-15 2023-08-02 Research Institute at Nationwide Children's Hospital Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy
US20250235554A1 (en) 2021-10-25 2025-07-24 Novartis Ag Methods for improving adeno-associated virus (aav) delivery
EP4514839A1 (en) 2022-03-17 2025-03-05 Innoskel Hybrid promoters and their use in osteolysis syndrome
EP4511392A1 (en) 2022-03-17 2025-02-26 Innoskel Polynucleotides encoding the alpha-1 chain of human type ii collagen and methods of their use
CA3255627A1 (en) 2022-05-06 2023-11-09 Novartis Ag NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
EP4536816A1 (en) 2022-06-09 2025-04-16 Genethon N-terminal truncated gde for the treatment of glycogen storage disease iii
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins
TW202426017A (zh) * 2022-11-24 2024-07-01 俄羅斯聯邦商拜奧卡德聯合股份公司 非包膜病毒的藥物組合物
CN121420060A (zh) 2023-06-29 2026-01-27 吉尼松公司 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶
EP4606892A1 (en) 2024-02-23 2025-08-27 Merck Patent GmbH Methods for the production of viral particles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420977B (sv) * 1976-03-18 1981-11-16 Kabi Ab Forfarande for rening och isolering av hepatitvirus for vaccinframstellning
JP4492826B2 (ja) * 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US7732129B1 (en) * 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US6566118B1 (en) * 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2799545A1 (en) * 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
ES2285120T3 (es) * 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019524101A (ja) * 2016-07-21 2019-09-05 スパーク セラピューティクス インコーポレイテッドＳｐａｒｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP7153009B2 (ja) 2016-07-21 2022-10-13 スパーク セラピューティクス インコーポレイテッド 高収率の組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクターを生成するための、規模拡大可能な高回収率の方法、及びそれにより生成される組換えアデノ随伴ウイルス（ｒＡＡＶ）ベクター
JP2021505610A (ja) * 2017-12-05 2021-02-18 アプライド ジェネティック テクノロジーズ コーポレイション ウイルス粒子のための製剤最適化
JP2021533757A (ja) * 2018-08-10 2021-12-09 リジェネクスバイオ インコーポレイテッド 組換えａａｖ生成のためのスケーラブルな方法
JP2023113623A (ja) * 2019-04-19 2023-08-16 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP7669414B2 (ja) 2019-04-19 2025-04-28 レジェンクスバイオ インコーポレーテッド アデノ随伴ウイルスベクター製剤及び方法
JP2023536883A (ja) * 2020-08-07 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド 高度に精製されたウイルス粒子のための製剤

Also Published As

Publication number Publication date
MXPA06014030A (es) 2007-10-08
BRPI0511764B1 (pt) 2017-10-24
MX2019006353A (es) 2022-06-27
US7704721B2 (en) 2010-04-27
ES2932278T3 (es) 2023-01-17
WO2005118792A1 (en) 2005-12-15
EP3290513B1 (en) 2022-09-07
US20060035364A1 (en) 2006-02-16
EP4170024A1 (en) 2023-04-26
DK3290513T3 (da) 2022-12-12
JP2019058177A (ja) 2019-04-18
HUE060433T2 (hu) 2023-03-28
CA2569244C (en) 2017-02-14
MX360727B (es) 2018-11-14
BRPI0511764B8 (pt) 2021-05-25
JP2014111625A (ja) 2014-06-19
JP2012143233A (ja) 2012-08-02
US20160083694A1 (en) 2016-03-24
CA2569244A1 (en) 2005-12-15
ES2647477T3 (es) 2017-12-21
JP2016195587A (ja) 2016-11-24
EP3290513A1 (en) 2018-03-07
US9051542B2 (en) 2015-06-09
EP1751275B1 (en) 2017-08-16
DK1751275T3 (da) 2017-11-27
US20170247664A1 (en) 2017-08-31
HUE035418T2 (en) 2018-05-02
JP5769650B2 (ja) 2015-08-26
BRPI0511764A (pt) 2008-01-08
EP1751275A4 (en) 2008-01-23
EP1751275A1 (en) 2007-02-14
US20110076744A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
JP5769650B2 (ja) Ａａｖベクターの凝集を防ぐための組成物およびその方法
Huang et al. AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications
US20220072073A1 (en) Methods of heat inactivation of adenovirus
US10294452B2 (en) Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
Lagor et al. Adeno-associated viruses as liver-directed gene delivery vehicles: focus on lipoprotein metabolism
CN108085301A (zh) 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
KR102205026B1 (ko) 시험관내에서 생성된 바이러스의 정제 방법 및 그 바이러스에 대한 제거 분석 방법
CN101018858A (zh) 防止aav载体聚集的组合物和方法
HK40091911A (en) Compositions and methods to prevent aav vector aggregation
JP7591579B2 (ja) 核磁気共鳴緩和測定によってａａｖ粒子のローディング状態を決定するための方法
Tamura et al. Production of Adeno-Associated Virus Vector Serotype rh. 10 and Optimization of Its Purification via Chloroform Extraction
US20230374468A1 (en) Formulations for viral vectors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110530

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110622

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111025

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140120